Carcinome parathyroïdien · ligne 1 · Aucune
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
Contenu clinique provisoire : il ne s'agit pas d'une ordonnance. Un oncologue doit vérifier les sources originales, l'applicabilité et le statut de révision.
| Ligne thérapeutique | 1 |
|---|---|
| Voie | local_therapy |
| Régime lié | None |
| ID | IND-PARATHYROID-CARCINOMA-1L-RESECTION |
|---|---|
| Type | Indication |
| État | examinés 2026-07-11 |
| Maladies | DIS-PARATHYROID-CARCINOMA |
| Sources | SRC-NCCN-NET-2025 SRC-NCCN-THYROID-2025 |
Notes
STUB — coverage-enabling local-therapy indication for DIS-PARATHYROID-CARCINOMA. Requires endocrine-surgery / endocrine- oncology co-lead signoff before clinical publication (CHARTER §6.1 — dev-mode-exempted, safe to merge as draft content). No systemic or adjuvant drug regimen is indicated for localized, completely resected disease — surgery alone is standard of care; `recommended_regimen` is intentionally left unset (surgery-only local_therapy track, mirroring IND-MENINGIOMA-1L-RESECTION-RT). This Indication deliberately does NOT use the `phases:` / `surgery_id` mechanism (as IND-MENINGIOMA-1L-RESECTION-RT does via SUR-MENINGIOMA-RESECTION) because no Surgery entity for the en-bloc parathyroidectomy procedure has been authored yet — a follow-up authoring pass should add a Surgery/Procedure entity (proposed id SUR-PARATHYROID-EN-BLOC-RESECTION under knowledge_base/hosted/content/procedures/) and wire it via `phases` for full parity with the Meningioma pattern. The full procedure (en- bloc resection of the parathyroid tumor + ipsilateral thyroid lobe + central lymph nodes, no capsule violation) is described here in prose (rationale / do_not_do) in the interim.
Utilisé par
Algorithmes
ALGO-PARATHYROID-CARCINOMA-1L- ALGO-PARATHYROID-CARCINOMA-1L
Maladie
DIS-PARATHYROID-CARCINOMA- Carcinome parathyroïdien
Indication
IND-PARATHYROID-CARCINOMA-2L-CINACALCET- IND-PARATHYROID-CARCINOMA-2L-CINACALCET